On Monday, Prime Medicine Inc (NASDAQ: PRME) opened higher 8.63% from the last session, before settling in for the closing price of $3.94. Price fluctuations for PRME have ranged from $1.11 to $6.94 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -124.13% over the past five years. Company’s average yearly earnings per share was noted 19.76% at the time writing. With a float of $93.82 million, this company’s outstanding shares have now reached $180.31 million.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 48.03%, while institutional ownership is 38.19%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.31 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.31) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.13% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 6.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 129.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.93 in one year’s time.
